Research Alert: Zbh Q1 Tops Estimates, Fueled By Diversified Portfolio And Strategic Growth
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Zimmer Biomet delivered solid Q1 2026 results with net sales of $2.087B (+9.3% reported, +2.9% organic constant currency), $20M above the consensus view, and adjusted EPS of $2.09 (+15.5% Y/Y), beating the consensus by $0.23. Performance was broad-based across U.S. markets at $1.209B (+3.2% Y/Y organic) and international operations at $877.4M (+2.5% Y/Y organic). The diversified portfolio enabled resilient performance with knees at $828.6M (+1.8% organic), hips at $524.1M (+3.2% organic), and S.E.T. serving as a growth engine with sales at $562.2M, benefiting from the Paragon 28 acquisition. Management raised full-year EPS guidance to $8.40-$8.55 from $8.30-$8.45 while maintaining revenue guidance of 2.5%-4.5% reported growth. Key milestones in Q1 included mBos robotic system enrollment completion in India, first G7 Acetabular System case following FDA clearance, and Dr. Vigdorchik's appointment as Chief Science Officer.
